DelveInsight has launched a new report on Non Muscle Invasive Bladder Cancer Pipeline
Non-muscle invasive bladder cancer (NMIBC) formerly known as superficial bladder cancer, is a common, heterogeneous disease associated with high rates of recurrence that often requires lifelong surveillance. The cancer is found in the tissue that lines the inner surface of the bladder wherein the bladder muscle is not involved.
Request for free sample copy- https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-pipeline-insight
Non Muscle Invasive Bladder Cancer Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of Non Muscle Invasive Bladder Cancer Pipeline products with detailed clinical profiles, key cross -competition, launch date along with product development activities.
Non Muscle Invasive Bladder Cancer Pipeline
The high-grade NMIBC pipeline possesses potential drugs in mid and late stage developments to be launched in the near future. The major key players include Viventia Bio/Sesen Bio (Vicinium), FKD Therapies Oy/Ferring Pharmaceuticals (Adstiladrin), CG Oncology (CG0070), ImmunityBio/Altor Biosciences (N-803 (ALT-803)), Theralase (TLD-1433), Merck (Keytruda) and others that hold the potential to create a significant positive shift in NMIBC in the market size.
Marketed drugs included in the report
Emerging drugs included in the report
Non Muscle Invasive Bladder Cancer Treatment
The main treatments when the cancer cells are found only in the bladder’s inner lining (non-muscle-invasive bladder cancer) are surgery, intravesical immunotherapy (BCG) andintravesical chemotherapy. Surgery, on its own or combined with other treatments, is used in most cases.
The market is expected to grow by factors like the expected entry of emerging therapies with novel targets and pricing. Furthermore, the upcoming products such as Adstiladrin, Vicinium, N-803, TLD-1433, CG0070 and Keytruda are anticipated to expand the market with a deeper penetration in the 7MM.
Non Muscle Invasive Bladder Cancer Symptoms
Non Muscle Invasive Bladder Cancer Report Highlights
Table of content
Introduction
Executive Summary
Non-muscle invasive bladder cancer: Overview
Pipeline Therapeutics
Therapeutic Assessment
Non-muscle invasive bladder cancer – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Non-muscle invasive bladder cancer Collaboration Deals
Late Stage Products
Vicinium : Sesen Bio
APL-1202: Asieris Pharmaceuticals
Mid Stage Products
UGN-102: UroGen Pharma
Balversa: Janssen Pharmaceuticals
Early Stage Products
UGN-201: UroGen Pharma
E7766: H3 Biomedicine
Pre-clinical and Discovery Stage Products
ATX 101: APIM Therapeutics
Inactive Products
Non Muscle Invasive Bladder Cancer Key Companies
Non Muscle Invasive Bladder Cancer Key Products
Non Muscle Invasive Bladder Cancer- Unmet Needs
Non Muscle Invasive Bladder Cancer- Market Drivers and Barriers
Non Muscle Invasive Bladder Cancer- Future Perspectives and Conclusion
Non Muscle Invasive Bladder Cancer Analyst Views
Appendix
Related Reports
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/